Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 174,300 shares, an increase of 61.8% from the March 31st total of 107,700 shares. Based on an average daily volume of 257,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the company’s shares are sold short.

Coeptis Therapeutics Stock Up 4.0 %

Shares of NASDAQ:COEP opened at $0.33 on Friday. Coeptis Therapeutics has a 1 year low of $0.29 and a 1 year high of $2.19. The company has a market cap of $12.08 million, a PE ratio of -0.40 and a beta of -0.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. The stock’s 50-day moving average is $0.40 and its 200 day moving average is $0.73.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Coeptis Therapeutics will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC grew its position in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,520,000 shares of the company’s stock after acquiring an additional 1,308,000 shares during the period. Armistice Capital LLC owned about 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent quarter. 13.88% of the stock is currently owned by institutional investors and hedge funds.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.